1Hope KJ,Jin L,Dick JE. Acute myeloid leukemia originates from a hierarchy of leukemic stem ceil classes that differ in self-renewal capacity[J]. Nat Immunol, 2004,5 (7) :738.
2Cozzio A,Passegue E,Ayton PM, et al. Similar MLL-associated leukemias arising from self-renewing stem cells and short-lived myeloid progenitors[J]. Genes Dev, 2003, 17(24) :3029.
3Huntly BJ,Gilliland DG. Leukaemia stem cells and the evolution of cancer-stem-cell research[J]. Nat Rev Cancer,2005,5(4):311.
4Jordan CT. Cancer stem cell biology: from leukemia to solid tumors[J]. Curr Opin Cell Biol, 2004,16 (6) : 708.
5Guzman ML, Neering SJ,Upchurch D, et al. Nuclear factor-kappaB is constitutively activated in primitive human acute myelogenous leukemia cells[J]. Blood, 2001,98 (8) : 2301.
6Gilliland DG,Jordan CT, Felix CA. The molecular basis of leukemia[J]. Hematology Am Soc Hematol Educ Program,2004,24(1):80.
7Guzman ML,Swiderski CF, Howard DS, et al. Preferential induction of apoptosis for primary human leukemic stem cells[J]. Proc Natl Acad Sci USA, 2002,99 (25) : 16220.
8Guzman ML, Upchurch D,Grimes B, et al. Expression of tumor-suppressor genes interferon regulatory factor 1 and death-associated protein kinase in primitive acute myelogenous leukemia cells[J]. Blood,2001 ,97(7) :2177.
9Guzman ML, Neering SJ, Upchurch D,et al. Nuclear factor-kappaB is constitutively activated in primitive human acute myelogenous leukemia cells[J]. Blood, 2001,98 (8) : 2301.
10Dean M,Fojo T,Bates S. Tumour stem cells and drug resistance[J]. Nat Rev Cancer, 2005 , 5 (4) : 275.
3McWILLIAMS A, LAM B, SUTEDJA T. Early proximallung cancer diagnosis and treatment[J].Eur RespirJ、2009, 33(3):656-665.
4BURSTEIN H J,MANGU P B, SOMERFIELD M R,et al. American Society of Clinical Oncologyclinical practice guideline update on the use ofchemotherapy sensitivity and resistance assays[J]J CUn Oncol, 2011,29(24):3328-3330.
5BAKER M. Cancer stem ceils tracked[J].Nature,2012, 488(7409):13-14.
6GANGEMI R,PALEARI L,ORENGO A M, et al.Cancer stem cells: a new paradigm forunderstanding tumor growth and progressionand drug resistance[J] Curr Med Chem, 2009,16(14):1688-1703.
7DEAN M, FOJO T, BATES S, Tumour stem cellsand drug resistance[J].Nat Rev Cancer, 2005,5(4):275-284.
8WANG Y L, ZHU B J, QI Z Z, et al. Aktl enhancesCA916798 expression through mTOR pathway[J].PloS one, 2013, 8(5):e62327.
9JUNG M J, RHO J K, KIM Y M, et al. Upregulation ofCXCR4 is functionally crucial for maintenance ofsternness in drug-resistant non-small cell lungcancer cells[J] Oncogene, 201 3, 32(2):209-221.
10LEVINA V, MARRANGONI A M, DeMARCO R,et al.Drug-selected human lung cancer stem cells:cytokine network, tumorigenic and metastaticpropertiesUl- PLoS One, 2008, 3(8):e3077.
